Background: Langerhans cell histiocytosis (LCH), a rare inflammatory myeloid neoplasm, exhibits a propensity for disparate clinical outcomes and prognoses across diverse patients. Nevertheless, definitive research findings elucidating the risk factors predisposing to the disease’s mortality remain elusive. Methods: A comprehensive review of the extant literature was undertaken across esteemed databases, including PubMed, Embase, Web of Science, and the Cochrane Library, extending from the inception of these repositories to June 24, 2024. The objective was to ascertain the studies examining the risk factors implicated in the mortality of LCH patients. A rigorous application of predetermined inclusion and exclusion criteria was employed to ascertain the eligibility of the selected studies. The analysis predominantly focused on the extraction of data pertaining to the odds ratios (OR), relative risks (RR), and hazard ratios (HR), along with their respective 95% confidence intervals (CI), as reported in the studies on the mortality risk factors associated with LCH patient populations. Results: This analysis included 30 studies involving 4,537 patients. Our meta-analytical investigation elucidated robust associations between mortality rates in LCH patients and the following factors: age younger than 2 years (OR:1.69,95%CI:1.14-2.49,P=0.009), multi-systemic involvement (OR:9.49,95%CI:4.19-21.49,P<0.00001), risk-organ involvement (OR:13.46,95%CI:9.44-19.19,P<0.00001), liver involvement (OR:7.61,95%CI:2.72-21.31,P=0.0001), hematopoietic involvement (OR:4.71,95%CI:1.53-14.49,P=0.007), gastrointestinal involvement (OR:3.44,95%CI:1.47-8.05,P=0.004), bone involvement (OR:0.29,95%CI:0.11-0.75,P=0.01), pulmonary involvement (OR:1.88,95%CI:1.13-3.12,P=0.01), lymph node involvement (OR:2.45,95%CI:1.31-4.58,P=0.005), skin involvement (OR:2.89,95%CI:1.09-7.64,P=0.03), and a non-active disease (NAD) response at 6 weeks (OR:0.06,95%CI:0.01-0.44,P=0.005). Conclusion: LCH patients with multi-system, risk-organ, hepatic, hematopoietic, gastrointestinal, pulmonary, lymph node, or skin involvement demonstrate an increased risk of mortality. Conversely, the involvement of bone or NAD response at 6 weeks suggest a reduced risk of mortality. Systematic review registration: PROSPERO, identifier CRD42024590087